왼쪽 번들 지점 영역의 안전성 및 효과가 심부전에서의 기존 심장 재 동기화 요법 (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jacqueline Beaulieu
- 전화번호: 1-800-227-3422
- 이메일: jacqueline.beaulieu@bsci.com
연구 장소
-
-
Alabama
-
Huntsville, Alabama, 미국, 35801
- 모병
- Heart Center Research, LLC
-
연락하다:
- John Jennings, Dr.
-
수석 연구원:
- John Jennings, Dr.
-
Mobile, Alabama, 미국, 36608
- 모병
- Mobile Infirmary Medical Center
-
연락하다:
- Ernest Matthew Quin, Dr.
-
수석 연구원:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, 미국, 85054
- 모병
- Mayo Clinic Phoenix
-
연락하다:
- Mayank Sardana, MD
-
수석 연구원:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, 미국, 72401
- 모병
- Arrhythmia Research Group
-
연락하다:
- Devi Nair, Dr.
-
수석 연구원:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, 미국, 92037
- 모병
- Scripps Memorial Hospital
-
연락하다:
- Nicolas Olson, MD
-
수석 연구원:
- Nicolas Olson, MD
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars Sinai Medical Center
-
수석 연구원:
- Ashkan Ehdaie, MD
-
연락하다:
- Ashkan Ehdaie, MD
-
Oakland, California, 미국, 94609
- 모병
- Alta Bates Summit Medical Center
-
연락하다:
- Rajan Shah, Dr.
-
수석 연구원:
- Rajan Shah, Dr.
-
Santa Monica, California, 미국, 90404
- 모병
- Pacific Heart Institute
-
연락하다:
- Stephen Tang, MD
-
수석 연구원:
- Stephan Tang, MD
-
Torrance, California, 미국, 90505
- 모병
- Torrance Medical Center
-
수석 연구원:
- Gene Kim, MD
-
연락하다:
- Gene Kim, MD
-
Ventura, California, 미국, 93003
- 모병
- Cardiology Associates Medical Group, Inc.
-
연락하다:
- Jonathan Dukes, Dr.
-
수석 연구원:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Washington Hospital Center
-
연락하다:
- Cyrus Hadadi, MD
-
수석 연구원:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, 미국, 34239
- 모병
- Sarasota Memorial Hospital
-
연락하다:
- Antonio Moretta, Dr.
-
수석 연구원:
- Antonio Moretta, Dr.
-
Tampa, Florida, 미국, 33613
- 모병
- AdventHealth Tampa
-
수석 연구원:
- Kenneth Yamamura, MD
-
연락하다:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, 미국, 30309
- 모병
- Piedmont Hospital
-
연락하다:
- Kavita Krishnasamy, MD
-
수석 연구원:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University Hospital
-
연락하다:
- Anand Shah, MD
-
수석 연구원:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, 미국, 83642
- 모병
- St. Luke's Idaho Cardiology Associates
-
연락하다:
- Justice Oranefo, MD
-
수석 연구원:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, 미국, 60521
- 모병
- University of Chicago
-
연락하다:
- Shrinath Yeshwant, MD
-
수석 연구원:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, 미국, 60540
- 빼는
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- 모병
- Community Heart and Vascular Hospital
-
연락하다:
- Krishna Malineni, MD
-
수석 연구원:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa Hospitals and Clinics
-
수석 연구원:
- Paari Dominic, MD
-
연락하다:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40207
- 모병
- Baptist Hospital East Louisville
-
수석 연구원:
- Kevin Parrott, MD
-
연락하다:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, 미국, 02720
- 모병
- Southcoast Physicians Group
-
연락하다:
- Arnoldas Giedrimas, MD
-
수석 연구원:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Hospitals
-
수석 연구원:
- Thomas Crawford, MD
-
연락하다:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, 미국, 49525
- 모병
- Corewell Health
-
연락하다:
- Jawad Wassim, MD
-
수석 연구원:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, 미국, 55805
- 빼는
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, 미국, 56303
- 빼는
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, 미국, 07932
- 모병
- Morristown Medical Center
-
연락하다:
- Michael Katz, MD
-
수석 연구원:
- Michael Katz, MD
-
-
New York
-
Albany, New York, 미국, 12211
- 모병
- Capital Cardiology Associates
-
연락하다:
- Rizwan Alimohammad, MD
-
수석 연구원:
- Rizwan Alimohammad, MD
-
Flushing, New York, 미국, 11355
- 모병
- New York Hospital Queens
-
연락하다:
- Seth Goldbarg, Dr.
-
수석 연구원:
- Seth Goldbarg, Dr.
-
New York, New York, 미국, 10021
- 모병
- Weill Cornell Medical University
-
연락하다:
- Jim Cheung, Dr.
-
수석 연구원:
- Jim Cheung, Dr.
-
New York, New York, 미국, 14621
- 모병
- Rochester General Hospital
-
연락하다:
- Dmitry Chuprun, MD
-
수석 연구원:
- Dmitry Chuprun, MD
-
Syracuse, New York, 미국, 13057
- 모병
- SUNY-Upstate Medical University
-
연락하다:
- Jorge Romero, MD
-
수석 연구원:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- 모병
- Sanger Heart and Vascular Institute
-
연락하다:
- Navid Nafissi, MD
-
수석 연구원:
- Navid Nafissi, MD
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
연락하다:
- Daniel Friedman, MD
-
수석 연구원:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, 미국, 43219
- 모병
- Mount Carmel Health System
-
연락하다:
- Kamel Addo, MD
-
수석 연구원:
- Kamel Addo, MD
-
Columbus, Ohio, 미국, 43214
- 모병
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
연락하다:
- Anish Amin, MD
-
수석 연구원:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Penn Presbyterian Medical Center
-
연락하다:
- John Bullinga, MD
-
수석 연구원:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, 미국, 18702
- 모병
- Geisinger Wyoming Valley
-
수석 연구원:
- Pugazhendhi Vijayaraman, MD
-
연락하다:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57108
- 모병
- Avera Heart Hospital of South Dakota
-
연락하다:
- Christopher Stanton, Dr.
-
수석 연구원:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37205
- 모병
- St.Thomas Health
-
연락하다:
- Ricardo Lugo, MD
-
수석 연구원:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, 미국, 75093
- 모병
- Heart Hospital Baylor Plano
-
연락하다:
- Mustafa Dohadwala, MD
-
수석 연구원:
- Mustafa Dohadwala, MD
-
Tyler, Texas, 미국, 75701
- 모병
- Christus Trinity Mother Frances Health System
-
연락하다:
- Stanislov Weiner, Dr.
-
수석 연구원:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Medical Center
-
수석 연구원:
- Pamela Mason, MD
-
연락하다:
- Pamela Mason, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
실험적: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
기간: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
기간: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Win ratio composite assessment
기간: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
기간: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
기간: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- C2403
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .